Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists
Affiliations
- PMID: 28991932
Item in Clipboard
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists
J Fam Pract.
2017 Oct.
Abstract
Since 2005, four new GLP-1RAs (liraglutide, albiglutide, dulaglutide, and lixisenatide) and a once-weekly formulation of exenatide were approved for the treatment of persons with T2DM. Another GLP-1RA, semaglutide, is under review by the FDA, as is exenatide administered via an osmotic mini-pump.
Similar articles
-
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.Diabetes Obes Metab. 2017 Jul;19(7):953-961. doi: 10.1111/dom.12902. Epub 2017 Mar 16. Diabetes Obes Metab. 2017. PMID: 28181725 Free PMC article.
-
Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.J Med Econ. 2016 Dec;19(12):1127-1134. doi: 10.1080/13696998.2016.1203329. Epub 2016 Jun 28. J Med Econ. 2016. PMID: 27310712
-
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?Diabetes Metab Res Rev. 2019 Jan;35(1):e3070. doi: 10.1002/dmrr.3070. Epub 2018 Oct 4. Diabetes Metab Res Rev. 2019. PMID: 30156747 Review.
-
A Plethora of GLP-1 Agonists: Decisions About What to Use and When.Curr Diab Rep. 2016 Dec;16(12):120. doi: 10.1007/s11892-016-0823-6. Curr Diab Rep. 2016. PMID: 27766579 Review.
-
Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.JAAPA. 2020 Aug;33(S8 Suppl 1):3-18. doi: 10.1097/01.JAA.0000669456.13763.bd. JAAPA. 2020. PMID: 32756220 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical